Ensysce Biosciences Inc

ensysce.com

What Do They Do?

Develops prescription drug candidates for people with severe pain, including opioids designed to reduce misuse and overdose.

How Do They Make Money?

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $10.2M in FY2025.

Operating income, FY2025

−202% of revenue

▲ +52% (Loss) vs FY2024 (−$6.7M, −129%)

Net income, FY2025

−201% of revenue

▲ +27% (Loss) vs FY2024 (−$8M, −153%)

Free cash flow, FY2025

−157% of revenue

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −15%; vs $1.4M in Q2 FY2025
Net income: ▲ +48% (Loss); vs −$1.7M in Q2 FY2025

Aug 25, 2026 Nasdaq set new listing steps after the Cy acquisition The post-transaction company must satisfy initial listing criteria; Nasdaq also granted until February 22, 2027, to regain bid-price compliance.
Aug 6, 2026 Acquired Cy Biopharma and added a CRPS candidate The acquisition adds CY-200, a clinical-stage candidate for complex regional pain syndrome.

Growing. Revenue grew 43% in 4 years, from $3.5M in FY2021 to $5.1M in FY2025, about 9% a year.

Who Do They Compete With?

Competes with Daiichi Sankyo, Purdue Pharma, Collegium Pharmaceutical, Pfizer, Endo Health Solutions, Nektar Therapeutics, Teva Pharmaceutical, Egalet, KemPharm, Elysium Therapeutics, Acura Pharmaceutical, and Vertex

Comments